Sunday, March 29, 2015: 5:20 PM-6:30 PM
International Ballroom (Hilton Chicago)
Description: Four interesting presentations regarding cervix cancer screening, trogh the use of proliferation biomarkers and genotyping biomarkers,An overview of the prevalence of different HPV types in US population,the introduction of a novel technique in order to reduce the number of colposcopies and biopsies after an abnormal PAP smear, and finally a cervical cancer risk determination with more than a million women, using a cotesting approach.
Moderators: Audrey Tieko Tsunoda, MD, Barretos Cancer Hospital, Barretos, Brazil and Rene Pareja, MD, Instituto de Cancerología - Las Américas, Medellín, Colombia
5:20 PM
Introductory Remarks
A. T. Tsunoda1 and R. Pareja2
1Barretos Cancer Hospital, Barretos, Brazil, 2Instituto de Cancerología - Las Américas, Medellín, Colombia
5:25 PM
Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent HPV vaccine
W. K. Huh1, C. M. Behrens2, J. Monsonego3, T. Cox4, M. T. Sandri5, P. S. Yap2 and E. L. Franco6
1University of Alabama at Birmingham, Birmingham, AL, 2Roche Molecular Systems, Pleasanton, CA, 3Institut du Col, Paris, France, 4University of California, Santa Barbara, CA, 5Istituto Europeo di Oncologia, Milan, Italy, 6McGill University, Montreal, QC, Canada
5:36 PM
HPV primary screening incorporating genotyping and p16/Ki-67 dual-stained cytology to determine which HPV positive women would benefit from colposcopy
T. C. Wright1, C. M. Behrens2, R. Ridder3, A. Sharma2 and P. S. Yap2
1Columbia University College of Physicians and Surgeons, New York, NY, 2Roche Molecular Systems, Pleasanton, CA, 3Ventana Medical Systems, Tucson, AZ
5:47 PM
Cervical cancer risk following three rounds of human papillomavirus (HPV) and cytology co-testing in a one million-women cohort
P. E. Castle1,2, F. H. Zhao3, W. K. Kinney4, L. Cheung5, M. Schiffman6, B. Fetterman7, N. Poitras7, T. Lorey7, J. Gage6, N. Wentzensen6 and H. Katki6
1Global Coalition Against Cervical Cancer, Arlington, VA, 2Albert Einstein College of Medicine, New York, NY, 3Cancer Institute Chinese Academy of Medical Sciences, Beijing, China, 4The Permanente Medical Group, Sacramento, CA, 5Information Management Services, Calverton, MD, 6National Cancer Institute, Bethesda, MD, 7The Permanente Medical Group, Berkeley, CA
5:58 PM
High-resolution microendoscopy (HRME): a low-cost, point-of-care alternative to colposcopy and biopsies?
K. M. Schmeler1, J. T. G. Fregnani2, B. Grant3, J. P. Resende4, C. Scapulatempo-Neto2, G. Macedo4, M. H. Stoler5, P. E. Castle6 and R. Richards-Kortum3
1The University of Texas MD Anderson Cancer Center, Houston, TX, 2Hospital de Câncer de Barretos, Barretos, Brazil, 3Rice University, Houston, TX, 4Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil, 5University of Virginia Health System, Charlottesville, VA, 6Albert Einstein College of Medicine, New York, NY
6:09 PM
Distillation
M. H. Einstein
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
